Characterization of Fasiglifam-Related Liver Toxicity in Dogs

Fasiglifam, a potent and highly selective agonist of G protein-coupled receptor 40, was developed for the treatment of type 2 diabetes mellitus. However, phase III clinical programs were terminated owing to liver safety concerns. Fasiglifam-related liver toxicity was also observed in repeat-dose dog toxicology studies, characterized by granulomatous inflammation with crystal formation in the liver and/or bile ducts. These histopathological changes were not observed in rat toxicology studies. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of dog liver sections obtained from a repeat-dose toxicology study indicated that the crystalline material in the affected dog liver contained fasiglifam and fasiglifam glucuronide (fasiglifam-G). Nonclinical mechanistic studies indicated that after 14 days of repeated oral dosing with [14C]fasiglifam at 200 mg/kg per day to dogs, the concentrations of fasiglifam and fasiglifam-G in the bile exceeded the solubility limit of these compounds in the bile (approximately 3000 µg/ml). After single oral 2- and 200-mg/kg doses administered to rats and dogs, fasiglifam and fasiglifam-G concentrations in dog bile were 5- to 10-fold higher than those in rat bile for the same dose of fasiglifam, while the bile flow rate adjusted by body weight was 4- to 8-fold lower in dogs than in rats. High fasiglifam and fasiglifam-G concentrations in dog bile together with lower bile flow rate could cause crystal formation in dog bile, resulting in secondary granulomatous inflammation in the dog liver.

[1]  Liping Pan,et al.  Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans , 2019, Xenobiotica; the fate of foreign compounds in biological systems.

[2]  L. Benet,et al.  Evaluation of the Relevance of DILI Predictive Hypotheses in Early Drug Development: Review of In Vitro Methodologies vs BDDCS Classification. , 2018, Toxicology research.

[3]  P. Watkins,et al.  Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience , 2018, Drug Safety.

[4]  Andy Z. X. Zhu,et al.  Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury , 2017, Toxicological sciences : an official journal of the Society of Toxicology.

[5]  K. Kaku,et al.  Long‐term safety and efficacy of fasiglifam (TAK‐875), a G‐protein‐coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52‐week open‐label phase III study , 2016, Diabetes, obesity & metabolism.

[6]  Xiaoyan Chen,et al.  Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury , 2015, Drug Metabolism and Disposition.

[7]  K. Kaku,et al.  Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial , 2015, Diabetes, obesity & metabolism.

[8]  S. Nudurupati,et al.  Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Normal or Varying Degrees of Impaired Renal Function , 2014, Drugs in R&D.

[9]  R. Fontana,et al.  Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. , 2014, Gastroenterology.

[10]  K. Kaku Fasiglifam as a new potential treatment option for patients with type 2 diabetes , 2013, Expert opinion on pharmacotherapy.

[11]  J. Chiang Bile acid metabolism and signaling. , 2013, Comprehensive Physiology.

[12]  S. Olafsson,et al.  Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. , 2013, Gastroenterology.

[13]  S. Asahi,et al.  Evaluation of low background liquid scintillation counter for non-clinical ADME studies , 2013, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  K. Brouwer,et al.  A Perspective on Efflux Transport Proteins in the Liver , 2012, Clinical pharmacology and therapeutics.

[15]  H. Hamadeh,et al.  Membrane Vesicle ABC Transporter Assays for Drug Safety Assessment , 2012, Current protocols in toxicology.

[16]  H. Naik,et al.  A Multiple‐Ascending‐Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK‐875, in Subjects With Type 2 Diabetes , 2012, Clinical pharmacology and therapeutics.

[17]  K. Maeda,et al.  Hepatic Uptake in the Dog: Comparison of Uptake in Hepatocytes and Human Embryonic Kidney Cells Expressing Dog Organic Anion-Transporting Polypeptide 1B4 , 2011, Drug Metabolism and Disposition.

[18]  K. Takeuchi,et al.  TAK-875, an Orally Available G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist, Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats , 2011, Journal of Pharmacology and Experimental Therapeutics.

[19]  Masahiro Ito,et al.  Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist. , 2010, ACS medicinal chemistry letters.

[20]  K. Brouwer,et al.  Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. , 2007, Molecular pharmaceutics.

[21]  P. Meier,et al.  Enterohepatic transport of bile salts and genetics of cholestasis. , 2005, Journal of hepatology.

[22]  Y. Sugiyama,et al.  In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[23]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[24]  K. Netter,et al.  The effects of sulphydryl reagents on the binding and mixed function oxidation of hexobarbital in rat hepatic microsomes. , 1975, Xenobiotica; the fate of foreign compounds in biological systems.